Remove Clinical Development Remove Hospitals Remove Therapies
article thumbnail

Beyond the Lab: Cell & Gene Therapy

Drug Target Review

Our inaugural report is a groundbreaking exploration of the remarkable advancements in cell and gene therapy that are revolutionising the field of drug discovery. Expert Insights We are honoured to have collaborated with renowned experts in the field of cell and gene therapy, who have generously shared their invaluable insights.

article thumbnail

The Expansion of Cell Therapies in Asia-Pacific

PPD

Cell and gene therapy (CGT) studies are rapidly gaining momentum in the Asia-Pacific region, fueled by growing patient demand and a thriving ecosystem of innovation. In China, the high incidence of solid tumors is driving an urgent need for advanced therapies, spurring the push for new treatment approaches.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

POLB 001: tackling cytokine storms before they start

Drug Target Review

In the ever-evolving landscape of immuno-oncology, managing the side effects of advanced therapies has become just as important as enhancing their efficacy. Existing therapies, such as tocilizumab, work by blocking specific inflammatory pathways but often come with limitations.

article thumbnail

Advancing neurological therapies with Dr Bruce Leuchter

Drug Target Review

Historically, what has limited investor interest in funding neurological and psychiatric therapies in development? Investors have historically taken a ‘guilty until proven innocent’ approach to investing in neuroscience therapies. All stakeholders have benefited from these innovations.

Therapies 104
article thumbnail

The FDA’s REMS Removal: A Watershed Moment for CAR T Access

Conversations in Drug Development Trends

Approximately two in 10 patients with hematologic malignancies are estimated to be eligible and able to receive cell therapy. The REMS Burden Explained Once deemed necessary for managing the risks associated with CAR T therapies, the REMS requirements imposed significant operational burdens on treatment centers.

article thumbnail

Alnylam Promotes Pushkal Garg to Chief R&D Officer

The Pharma Data

“As our science has advanced, so has the need for tighter alignment across Research and Development to ensure that we continue to scale our impact and transform the lives of patients across a growing number of diseases,” Greenstreet stated.

RNA 40
article thumbnail

Rilzabrutinib Cuts Flares in IgG4-Related Disease; Fast Track Granted in US

The Pharma Data

Fox Chair in Medicine at Massachusetts General Hospital, and Executive Chairman of The IgG4ward! This design was meant to enable clinician-researchers to gauge the ability of rilzabrutinib to control disease activity after the withdrawal of standard therapy. Fast Track and Orphan Drug Designations from FDA The U.S.

Disease 40